First-Line NALIRIFOX Demonstrates Survival Advantage Over St

Eileen M. O’Reilly, MD, expands on the updated survival data from NAPOLI-3, explains how NALIRIFOX could fit into the current pancreatic ductal adenocarcinoma treatment paradigm, and shares potential opportunities to build upon this research moving forward.

Related Keywords

California , United States , Los Angeles , New York , American , America , Astrazeneca Medimmune , Genentech Roche , Eileenm Oreilly , Zev Wainberg , Astrazeneca , Novartis , Genentech , Bristol Myers Squibb , University Of California , Los Angeles Health , Pancreatic Cancer Research , Davidm Rubenstein Center , Boehringer Ingelheim , Helio Health Incyte , Winthrop Rockefeller Endowed Chair , Medical Oncology , Medical Initiatives , Pancreatic Cancer , Neuroendocrine Cancers , Memorial Sloan Kettering Cancer Center , Cancers Symposium , North America , North American , Autem Medical , Helio Health , Marcus Ventures , Helsinn Healthcare , Puma Biotechnology , Nalirifox , Patients With Metastatic Pancreatic Ductal Adenocarcinoma , Eileenmo Reilly , D , Napoli 3 Trial , Nct04083235 ,